Literature DB >> 9636870

Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection.

J A al-Tawfiq1, K K Wools.   

Abstract

Infection with Sporothrix schenckii causes a localized lymphocutaneous disease in the immunocompetent host, while it frequently results in disseminated disease in the immunocompromised patient. There are a growing number of reports of S. schenckii infection in the human immunodeficiency virus (HIV)-infected population, where the disease usually starts as a localized cutaneous lesion and subsequently disseminates. The optimal treatment of systemic sporotrichosis in HIV-positive patients is as yet unknown. This article presents a case report of disseminated sporotrichosis in an HIV-infected patient, a review of the literature, and discussion of treatment options for HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636870     DOI: 10.1086/516356

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

2.  Use of mycelial-phase Sporothrix schenckii exoantigens in an enzyme-linked immunosorbent assay for diagnosis of sporotrichosis by antibody detection.

Authors:  Rodrigo Almeida-Paes; Monique A Pimenta; Claudia Vera Pizzini; Paulo Cezar F Monteiro; José Mauro Peralta; Joshua D Nosanchuk; Rosely Maria Zancopé-Oliveira
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

Review 3.  The impact of sporotrichosis in HIV-infected patients: a systematic review.

Authors:  José A S Moreira; Dayvison F S Freitas; Cristiane C Lamas
Journal:  Infection       Date:  2015-02-21       Impact factor: 3.553

Review 4.  Sporothrix schenckii and Sporotrichosis.

Authors:  Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; Armando Oliveira Schubach
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

5.  Virulence of Sporothrix schenckii conidia and yeast cells, and their susceptibility to nitric oxide.

Authors:  K S Fernandes; A L Coelho; L M Lopes Bezerra; C Barja-Fidalgo
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

6.  Impaired host defense against Sporothrix schenckii in mice with chronic granulomatous disease.

Authors:  Hideko Kajiwara; Mitsumasa Saito; Shouichi Ohga; Takeshi Uenotsuchi; Shin-ichi Yoshida
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Efficacy of posaconazole in murine experimental sporotrichosis.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

8.  Sporothrix schenckii lymphadentitis in a male with X-linked chronic granulomatous disease.

Authors:  Jessica R Trotter; Panida Sriaroon; David Berman; Aleksandra Petrovic; Jennifer W Leiding
Journal:  J Clin Immunol       Date:  2013-11-16       Impact factor: 8.317

Review 9.  Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment.

Authors:  Markus Ruhnke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Sporotrichosis: The Story of an Endemic Region in Peru over 28 Years (1985 to 2012).

Authors:  Max Carlos Ramírez Soto
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.